Abstracts tagged "spondyloarthritis"

Abstract Number: LB09 • ACR Convergence 2025
Rotation or Change of Biologic After TNF blocker treatment failure for axial Spondyloarthritis
Elisa Dalix¹, Philippe Goupille², Daniel Wendling³, Christian Roux⁴, Jean-Hughes Samon⁵, Olivier Brocq⁶, Anne Tournadre⁷, Arnaud Constantin⁸, Maxime Breban⁹, Gregoire Cormier¹⁰, Tristan Pascart¹¹, Thierry Lequerre¹², Pascal Claudepierre¹³, Eric Lespessailles¹⁴, Benoit Legoff¹⁵, Jeremie Sellam¹⁶, Athan Baillet¹⁷, Thierry Schaeverbeke¹⁸, Stephan Pavy¹⁹, Valerie Devauchelle-Pensec²⁰, Elisabeth Gervais²¹, Laure Gossec²², Corinne Miceli²³, Yves-Marie Pers²⁴, Cedric Lukas²⁵, Renaud Felten²⁶, Beatrice Bouvard²⁷, Amelie Denis²⁸, Emmanuelle Dernis²⁸, Emilie Presles²⁹, Florence Rancon²⁹ and Hubert Marotte³⁰, ¹Université Jean Monnet, CHU Saint-Etienne, Mines Saint-Etienne, INSERM, Saint-Etienne, France, ²Department of Rheumatology and INSERM-CIC¹⁴¹⁵, University Hospital of Tours, EA ⁷⁵⁰¹ GICC, University of Tours, Tours, France, ³Rhumatologie, CHU de Besançon, Besancon, France, ⁴Service de rhumatologie, CHU de Nice, IbV, Université Cote d'Azur, Nice, France, ⁵Service de Rhumatologie, Hôpital Maison Blanche, Centre Hospitalier Universitaire de Reims, Reims, France; Université de Reims Champagne-Ardenne, Faculté de Médicine, EA ³⁷⁹⁷, Reims, France, ⁶Rheumatology Department, CHPG Monaco, Monaco, Monaco, ⁷Rheumatology Department, CHU Clermont-Ferrand, Clermont-Ferrand, France, ⁸Rheumatology Center, Toulouse University Hospital, Toulouse, France, ⁹INSERM UMR¹¹⁷³, INFLAMEX, Laboratoire d'Excellence, Rheumatology Division, Ambroise Paré Hospital (AP-HP), Paris, France, ¹⁰Rheumatology, Centre Hospitalier Departemental Vendee, La Roche-sur-Yon, France, ¹¹Department of Rheumatology, Université Catholique de Lille Hôpital Saint Philibert, Lomme, France, ¹²Department of Rheumatology & CIC-CRB ¹⁴⁰⁴, Inserm, PANTHER UMR ¹²³⁴, University of Rouen Normandie, Normandie University, CHU Rouen, Rouen, France, ¹³AP-HP, Henri-Mondor Hospital, Department of Rheumatology, EpiDermE, Université Paris Est Créteil, Créteil, France, ¹⁴Translational Medicine Research Platform, PRIMMO, University Hospital Centre of Orleans, Orleans, France, ¹⁵Nantes Université, ONIRIS, Univ Angers, CHU Nantes, INSERM, Regenerative Medicine and Skeleton, RMeS, UMR ¹²²⁹, Nantes, France, ¹⁶Rheumatology Department, Sorbonne Université, Saint-Antoine Hospital Assistance Publique Hôpitaux de Paris (AP-HP), Centre de Recherche Saint-Antoine (CRSA) Inserm UMRS-⁹³⁸,, Paris, France, ¹⁷Université Grenoble Alpes, ⁴UMR⁵⁵²⁵, Grenoble, France, ¹⁸Department of Rheumatology, Hôpital Pellegrin, Bordeaux, France, ¹⁹Department of Rheumatology, Hôpital Bicêtre, Assistance Publique - Hôpitaux de Paris, Le Kremlin-Bicetre, ²⁰Department of Rheumatology, Université de Bretagne Occidentale, CHU Brest, INSERM (U¹²²⁷), LabEx IGO, Brest, France, ²¹LITEC, Université de Poitiers, CHU Poitiers, Poitiers, France, ²²Sorbonne Université, AP-HP & EULAR, Paris, France, ²³Immunoregulation Unit, Institut Pasteur, Cochin AP-HP, Paris, France, ²⁴IRMB, University of Montpellier, Inserm U¹¹⁸³, CHU Montpellier, Montpellier, France, ²⁵Rheumatology department, CHU and University of Montpellier, Montpellier, France; UMR UA¹¹ Inserm (IDESP), University of Montpellier, Montpellier, France, ²⁶Service de Rhumatologie, CHU de Strasbourg - Hôpital de Hautepierre, Strasbourg, France, ²⁷Rhumatologie, Centre Hospitalier Universitaire, Angers, France, ²⁸CH Le Mans, Le Mans, France, ²⁹CHU Saint-Etienne, CIC ¹⁴⁰⁸, Saint-Etienne, France, ³⁰Université Jean Monnet, CHU de Saint-Etienne, CIC ¹⁴⁰⁸, Mines Saint-Etienne, INSERM, SSINBIOSE ¹⁰⁵⁹, Saint-Etienne, France
Background/Purpose: Axial spondyloarthritis (axSpA) is initially treated with non-steroidal anti-inflammatory drugs. In case of inadequate response, ACR/EULAR recommend biological disease-modifying antirheumatic drugs (bDMARDs). Up to…
Abstract Number: 0386 • ACR Convergence 2025
Introducing the Multidimensional Pain Inventory as a Comprehensive Tool or Assessing Pain in Patients With Axial Spondyloarthritis
David Kiefer¹, Yade Sonkaya², Dietmar Krause³, Markus Voglau⁴, Bernhard Mintrop⁵, Imke Redeker⁶, Xenofon Baraliakos⁷ and Uta Kiltz⁷, ¹Ruhr-Universität Bochum; Private practice of rheumatology, Hattingen, Germany, Herne, Germany, ²Ruhr-Universität Bochum, Herne, Germany, ³Elisabeth-Gruppe, Herne, Germany, Essen, Germany, ⁴myself, Oldenburg, Germany, ⁵Private rheumatology practice, Hattingen, Germany, ⁶Ruhr University Bochum, Bochum, Germany, ⁷Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: The West Haven-Yale Multidimensional Pain Inventory (MPI) is a validated tool designed to assess the multidimensional aspects of chronic pain, including the 5 dimensions…
Abstract Number: 0540 • ACR Convergence 2025
Low-Dose CT reveals syndesmophyte progression in axial SpA, particularly in the thoracic spine: Insights from the SPACE cohort covering early and established disease
Manouk de Hooge¹, Mary Lucy Marques², Gizem Ayan³, Miranda van Lunteren⁴, Liese de Bruin⁴, Monique Reijnierse⁵, Désirée Van Der Heijde⁴, Sofia Ramiro⁶ and Floris A. van Gaalen⁴, ¹Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands; and Coimbra Local Health Unit, Coimbra, Portugal, ³Ankara Research and Training Hospital, Ankara, Turkey, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Department of Radiology, Leiden University Medical Center, Leiden, Netherlands, ⁶Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Low-dose computed tomography (ldCT) has not previously been used to assess pt with axial spondyloarthritis (axSpA) early in their disease course, especially those with…
Abstract Number: 0578 • ACR Convergence 2025
Real-world Effectiveness of Upadacitinib on Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Core Domains for Patients with Psoriatic Arthritis: Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Philip J. Mease¹, Xiaolan Ye², Christopher Saffore³, Thomas Iyile⁴, Nicole Middaugh⁵, Taylor Blachley⁵, Melissa Eliot⁵ and Alexis Ogdie⁶, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²AbbVie Inc., Mettawa, IL, ³AbbVie Inc., waukegan, IL, ⁴AbbVie Inc, North Chicago, IL, ⁵CorEvitas, LLC, Waltham, MA, ⁶Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE
Background/Purpose: Psoriatic arthritis (PsA) is a heterogenous inflammatory disease that can cause substantial impairment in quality of life in affected patients. The Group for Research…
Abstract Number: 1416 • ACR Convergence 2025
Structural Damage Progression in the Spine in Patients with Psoriatic Arthritis: Findings from a Longitudinal Cohort Study
Fadi Kharouf¹, Pankti Mehta², Virginia Carrizo Abarza³, Shangyi Gao⁴, Daniel Pereira⁵, Dafna D. Gladman⁶, Vinod Chandran⁷ and Denis Poddubnyy⁸, ¹University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ²University of Toronto, Gladman Krembil Psoriatic Arthritis Research Program, Toronto, ON, Canada, ³Toronto Western Hospital - University of Toronto, Toronto, ON, Canada, ⁴Gladman-Krembil Psoriatic Arthritis Research Program, Centre for Prognosis Studies in the Rheumatic Diseases, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Ontario, Canada, Toronto, ON, Canada, ⁵University Health Network, Toronto, ON, Canada, ⁶Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁷University of Toronto, Toronto, ON, Canada, ⁸Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany
Background/Purpose: Axial involvement is one of the key features of psoriatic arthritis (PsA) and is associated with increased disease burden. However, rates and predictors of…
Abstract Number: 1464 • ACR Convergence 2025
Incidence of Major Adverse Cardiovascular Events (MACE) in Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis Patients With and Without Cardiovascular Risk Factors Treated With Secukinumab: Five-Year Safety Data from the Real-World SERENA Study
Uta Kiltz¹, Petros Sfikakis², Andreas Bounas³, Nicola Gullick⁴, Eric LESPESSAILLES⁵, Jan Brandt-Juergens⁶, Rasho Rashkov⁷, Cynthia Vizcaya⁸, Andreas Clemens⁸, Lara Gómez⁹, Kim Hoyt¹⁰, Weibin Bao¹¹ and Karl Gaffney¹², ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²NKUA - SCHOOL OF MEDICINE, Athens, Greece, ³‘OLYMPION’, General Clinic of Patra, Patra, Greece, ⁴Rheumatology Department, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK, Coventry, United Kingdom, ⁵University Hospital of Orléans, Orleans, France, ⁶Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁷Clinic of Rheumatology, University Hospital St. Ivan Rilski, Sofia, Bulgaria, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Novartis Farmaceutica, Madrid, Spain, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹¹Novartis Pharmaceuticals Corporation, Hanover, NJ, ¹²Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom
Background/Purpose: Patients with psoriasis (PsO), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) are at increased risk of major adverse cardiovascular events (MACE) due to systemic…
Abstract Number: 2203 • ACR Convergence 2025
Maternal and Fetal Outcomes Associated with IL-17 Inhibitor Exposure During Pregnancy in Patients with Seronegative Arthritis: A Case Series of Nine
Arshdeep Waring¹, Sofia Rieger-Torres², Jeremiah Tan³, Viktoria Pavlova⁴ and Neda Amiri⁵, ¹University of British Columbia, Abbotsford, BC, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴McMaster University, Ancaster, ON, Canada, ⁵University of British Columbia, North Vancouver, BC, Canada
Background/Purpose: Interleukin-17 (IL-17) inhibitors, such as ixekizumab and secukinumab, are increasingly used in the treatment of seronegative inflammatory arthritis, including psoriatic arthritis and axial spondyloarthritis.…
Abstract Number: 2347 • ACR Convergence 2025
Bimekizumab Treatment Resulted in Patients with Axial Spondyloarthritis Maintaining Their Clinical Responses Over 3 Years: Results from Two Phase 3 Studies and Their Open-Label Extension
Fabian Proft¹, Désirée Van Der Heijde², Sergio Schwartzman³, Vanessa Taieb⁴, Sarah Kavanagh⁵, Gaëlle Varkas⁶, Victoria Navarro-Compan⁷ and Xenofon Baraliakos⁸, ¹Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Weill Cornell Medical Center, New York Presbyterian Hospital, and Hospital for Special Surgery, New York, NY, ⁴UCB, Colombes, France, ⁵UCB, Morrisville, NC, ⁶Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁷Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁸Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease which requires optimal management.1 In clinical trials, Assessment of SpondyloArthritis international Society ≥40% improvement (ASAS40) is…
Abstract Number: 0390 • ACR Convergence 2025
Radiographic Assessment in Juvenile Spondyloarthritis: Evaluating the axJSpA Criteria Using Radiographs Alone Versus MRI
David M. Biko¹, Nancy A. Chauvin², Michael Francavilla³, Nele Herregods⁴, Walter P. Maksymowych⁵, Robert G. W. Lambert⁶, Timothy Brandon¹, Ozgur Kasapcopur⁷, Mehmet YILDIZ⁸, Hemalatha Srinivasalu⁹ and Pamela Weiss¹⁰, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²The Cleveland Clinic, Hummelstown, PA, ³Department of Pediatric Radiology, Children’s Hospital Philadelphia, Philadelphia, PA, ⁴Ghent University Hospital, Ghent, Belgium, ⁵Department of Medicine, University of Alberta, ⁵⁶⁸ Heritage Building, Edmonton, AB, Canada, ⁶University of Alberta, Department of Radiology & Diagnostic Imaging, Edmonton, AB, Canada, ⁷Istanbul University-Cerrahpasa, Cerrahpasa Medical School, istanbul, Turkey, ⁸Istanbul University-Cerrahpasa Department of Pediatric Rheumatology, Istanbul, Turkey, ⁹Children's National Hospital, Washington, DC, ¹⁰Childrens Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Radiographs are neither sensitive nor reliable for assessing axial disease in juvenile spondyloarthritis (JSpA), though they are still used in some settings due to…
Abstract Number: 0541 • ACR Convergence 2025
Inflammatory Back Pain Is Not Associated With HLA-B27 Positivity or CRP Levels in a Nationally Representative U.S. Population
Mark Hwang¹, Seokhun Kim², Charles Green¹, Charles Dillon³, Shervin Assassi⁴, Michael Weisman⁵ and John Reveille⁶, ¹UTHealth Houston, Houston, TX, ²UTHealth Houston, Houston, ³NIH, Bethesda, MD, ⁴Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, ⁵Cedars-Sinai Medical Center, LOS ANGELES, CA, ⁶Department of Medicine, University of Texas Medical Center, Houston, TX
Background/Purpose: Inflammatory back pain (IBP) is a hallmark symptom of axial spondyloarthritis (axSpA) and is frequently used as a clinical entry point for further evaluation,…
Abstract Number: 0582 • ACR Convergence 2025
Long-Term Efficacy and Safety of Tofacitinib in Active Axial Spondyloarthritis: Experience from a Tertiary Care Center in South India
Prabhu Vasantha Kumar¹, John Mathew², Ashish Jacob Mathew³ and Ruchika Goel², ¹Christian Medical College, Vellore, Tamil Nadu, India, Vellore, Tamil Nadu, India, ²Christian Medical College, Vellore, Tamil Nadu, India, ³Christian Medical College, Vellore, India
Background/Purpose: Despite the good efficacy of bDMARDs in nearly 60% of patients with axial spondyloarthritis (AxSpA), high costs limit their use in resource-limited settings. Few…
Abstract Number: 1419 • ACR Convergence 2025
Effectivenss of an educational program on non-radiographic axial spondyloarthritis
Hideto Kameda¹, Toshihide Shuto², Akimichi Morita³, Yasuharu Nakashima⁴, Kiyoshi Matsui⁵, Masaaki Mori⁶ and Masahiro Yamamura⁷, ¹Department of Internal Medicine, Toho University, Tokyo, Japan, ²Chiyoda Hospital, Hyuga, Japan, ³Department of Geriatric and Environmental Dermatology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan, ⁴Kyushu University, Fukuoka, Japan, ⁵Amagasaki Chuo Hospital, Amagasaki, Japan, ⁶Institute of Science Tokyo, Tokyo, Japan, ⁷Okayama Saiseikai General Hospital, Okayama, Japan
Background/Purpose: Non-radiographic axial spondyloarthritis (nr-axSpA) is a relatively new disease concept. We developed an educational program to promote early and appropriate referral to specialists based…
Abstract Number: 1465 • ACR Convergence 2025
Sustainability of Clinical Response Through 2 Years Among Upadacitinib-Treated Patients With Axial Spondyloarthritis: Data From the SELECT-AXIS 1 and SELECT-AXIS 2 Trials
Victoria Navarro-Compan¹, Philip J. Mease², Lianne S. Gensler³, Martin Rudwaleit⁴, Yael Klionsky⁵, Jayne Stigler⁶, Erin Mancl⁷, Shirley Chen⁸, Jamie Urbanik⁹ and Xenofon Baraliakos¹⁰, ¹Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ²Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ³Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁴Bielefeld University, Medical School and University Medical Centre OWL, Klinikum Bielefeld, Department of Rheumatology, Bielefeld, Germany, ⁵Division of Rheumatology, Department of Medicine, Wake Forest School of Medicine, Winston-Salem, NC, ⁶AbbVie, Round Lake, IL, ⁷AbbVie, Chicago, IL, ⁸AbbVie, Somerset, NJ, ⁹AbbVie, Grayslake, IL, ¹⁰Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: Treatment with the oral JAK inhibitor upadacitinib (UPA) has shown efficacy and safety in patients with active axial spondyloarthritis (axSpA), including both radiographic (r-axSpA,…
Abstract Number: 2307 • ACR Convergence 2025
Peripheral Manifestations In Axial And Peripheral Spondyloarthritis: A Systematic Literature Review On Their Assessment In Clinical Trials
AUGUSTA ORTOLAN¹, Casper Webers², Elena Nikiphorou³, Alexandre Sepriano⁴, Louise Falzon⁵, Clementina López Medina⁶, Dafne capelusnik⁷, Désirée Van Der Heijde⁸, Anna Molto⁹ and Sofia Ramiro¹⁰, ¹Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy, ²Maastricht University Medical Centre, Maastricht, Netherlands, ³King's College London, London, United Kingdom, ⁴Department of Rheumatology, Leiden University Medical Centre, Portela Loures, Portugal, ⁵Sheffield Centre for Health and Related Research, University of Sheffield, Sheffield, United Kingdom, ⁶Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain, ⁷Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁹Assistance Publique Hôpitauxde Paris, Paris, France, ¹⁰Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Peripheral manifestations (peripheral arthritis, enthesitis, dactylitis) of axial spondyloarthritis (axSpA) and peripheral spondyloarthritis (pSpA) represent a significant burden for patients, but are understudied. Our…
Abstract Number: 2348 • ACR Convergence 2025
Efficacy and safety of dual biological therapy in the treatment of rheumatic diseases: experience from a single highly specialized center.
Francesco Fulvio Bizzarri¹, Luis Alberto Menchén Viso², Esther Chamorro De Vega³, Ofelia Baniandrés Rodríguez⁴ and Juan Carlos Nieto², ¹Hospital Universitario Clinico San Cecilio, Granada, Spain, ²Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³Pharmacy department, Hospital General Universitario Gregorio Marañón.Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain, Madrid, Madrid, Spain, ⁴Hospital General Universitario Gregorio Marañon, Madrid, Spain
Background/Purpose: Immune‐mediated rheumatic diseases (IMRDs) are chronic inflammatory disorders driven by multiple overlapping immunological pathways. Although biologic DMARD monotherapy has substantially improved outcomes, a subset…

1
2
3
…
49
Next Page »

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].